Akero Therapeutics (AKRO) | Stock Overview & Key Data
Akero Therapeutics Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $58.40 on January 27, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Akero Therapeutics
AKRO
|
4.50B Mid-cap | 0.29% | 0.94% | 22.48% | -0.11% | 51.93% | 89.17% | 16.40% | 114.40% | 177.41% | 177.41% | 177.41% |
|
Vertex
VRTX
|
109.45B Large-cap | -2.03% | -0.35% | -9.68% | -7.51% | -5.26% | 1.24% | 34.08% | 113.19% | 376.31% | 717.28% | 1,190.86% |
|
Regeneron
REGN
|
80.98B Large-cap | -1.40% | -12.73% | -19.27% | -14.47% | -20.27% | 25.39% | -16.92% | 20.10% | 53.41% | 959.24% | 4,557.42% |
|
Arrowhead
ARWR
|
10.42B Large-cap | -8.15% | -5.03% | 13.18% | 11.50% | 7.02% | 384.82% | 116.12% | 2.32% | 1,173.04% | 1,291.25% | 50.41% |
|
Bio-Techne
TECH
|
9.07B Mid-cap | 5.74% | -7.11% | -10.77% | -20.32% | -14.75% | 6.78% | -37.73% | -51.28% | 86.91% | 161.27% | 281.12% |
|
Corcept Therapeutics
CORT
|
4.84B Mid-cap | 9.00% | 40.79% | 105.92% | -13.17% | 90.18% | -10.40% | 198.75% | 224.57% | 1,093.99% | 1,292.59% | 1,378.51% |
Ownership & Short Interest
Calculate Your Akero Therapeutics Investment Returns
Long-Term Investment Performance Analysis
Akero Therapeutics stock price in Jun 2019 was $19.70, A $1,000.00 lump sum investment in Akero Therapeutics made 6 years ago would be worth approximately $2,774.11 today, representing a strong return of 177.41%. This translates to an annualized return (CAGR) of 17.05%.
6 Years 5 Months Investment Scenario (Jun 2019 - Dec 2025)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is AKRO's 52-week high and low?
- In the last 52 weeks, Akero Therapeutics reached a high of $58.40 (on January 27, 2025) and a low of $21.34 (on January 14, 2025).
- What is the market cap and P/E ratio for AKRO?
- Curious about Akero Therapeutics's size and valuation? Its market capitalization stands at 4.50B. When it comes to valuation, the P/E ratio (trailing twelve months) is -14.57, and the forward P/E (looking ahead) is -13.62.
- Does AKRO pay dividends? If so, what's the yield?
- As for dividends, Akero Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Akero Therapeutics's main competitors or similar companies to consider before investing?
When looking at Akero Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology 1.24% 34.08% Regeneron
REGN80.98B Healthcare Biotechnology 25.39% -16.92% Arrowhead
ARWR10.42B Healthcare Biotechnology 384.82% 116.12% Bio-Techne
TECH9.07B Healthcare Biotechnology 6.78% -37.73% Corcept Therapeutics
CORT4.84B Healthcare Biotechnology -10.40% 198.75% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Akero Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Akero Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -34.53%, the Debt to Equity ratio from the most recent quarter is 0.06, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for AKRO?
- Looking at Akero Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of AKRO stock is held by insiders and institutions?
- Wondering who owns Akero Therapeutics stock? Company insiders (like executives and directors) hold about 1.46% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 112.47%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.